Silk Road Medical, Inc.

Silk Road Medical, Inc. is a health care startup based in Sunnyvale, California, founded in 2007. The company specializes in reducing the risk of stroke through its pioneering treatment of carotid artery disease, known as TransCarotid Artery Revascularization (TCAR). This clinically proven procedure combines neuroprotection principles with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE® Transcarotid Neuroprotection and Stent System is specifically designed for TCAR in high surgical risk patients. The company recently secured a significant $100.00M post-IPO equity investment on 18 October 2022. Silk Road Medical's innovative approach to stroke prevention in carotid artery disease sets it apart in the health care industry. The company's commitment to improving patient outcomes aligns with the growing focus on advanced medical devices designed to address critical health issues. With its recent substantial investment, Silk Road Medical is poised to further develop and expand its groundbreaking TCAR procedure, contributing to the advancement of stroke risk reduction in high-risk patients. For more information on the company, please visit their website at http://silkroadmed.com.